Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Lambin, Philippe ^a   Ramaekers, Bram L T ^a   Van Mastrigt, Ghislaine A P G ^a   Van Den Ende, P ^a   De Jong, J ^a   De Ruysscher, Dirk K M ^a   Pijls Johannesma, Madelon ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ERYTHROPOIETIN; HEMOGLOBIN; NIMORAZOLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROMETHAZINE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SENSITIVITY; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 70049097226     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006158.pub2     Document Type: Review

References (40)

1. * Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-1260
2. Luksenburg H, Weir A, Wager R. Treatment of anemia associated with cancer chemotherapy. FDA briefing document; http://www.fda.gov/OHRMS/DOCKETS/ac/04/ briefing/4037B2-04-FDA-Aranesp-Procrit.doc 2004:43-49
3. * Hoskin PJ, Morgan DAL, Robinson M, Slevin N, Hope E. Erythropoetin supplementation for radical radiotherapy in head and neck cancer: interim analysis of a randomised phase III trial. Estro 21 abstract book. Prague, 2002:S175.
4. Luksenburg H, Weir A, Wager R. Treatment of anemia associated with cancer chemotherapy. FDA briefing document; http://www.fda.gov/OHRMS/DOCKETS/ac/04/ briefing/4037B2-04-FDA-Aranesp-Procrit.doc 2004:59-60.
5. Luksenburg H, Weir A, Wager R. Treatment of anemia associated with cancer chemotherapy. FDA briefing document http://www.fda.gov/OHRMS/DOCKETS/ac/04/ briefing/4037B2-04-FDA-Aranesp-Procrit.doc 2004:61-64.
6. * Machtay M. Phase III randomized study of radiotherapy with or without epoetin alfa in anemic patients with squamous cell carcinoma of the head and heck [Official title: A randomized phase III trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiotherapy for carcinoma of the head and neck]. Protocol ID: RTOG-9903 2006.
7. Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al. Definitive radiotherapy ± erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-103 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta GA, 2004:S132.
8. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, StrippDC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). International Journal of Radiation Oncology, Biology, Physics 2007;69(4):1008-1017 (Pubitemid 47625834)
9. Overgaard J. Examination of a new erythropoiese stimulating protein (Aranesp®) for the effects on radiotherapy to patients with primary squamous cell head and neck carcinoma [Undersøgelse af betydningen af Nyt Erythropoiese-Stimulerende Protein (Aranesp®) for effekten af strålebehandling til patienter med primært planocellulært hoved-hals karcinom]. http://www.dahanca.dk/get-media-file.php?mediaid=43 2002.
10. * Overgaard J, Hoff C, Sand Hansen H, Specht L, Overgaard M, Grau C, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Group DAHANCA 10 rand. European Journal of Cancer Supplements 2007;5(6):7.
11. * Rosen F, Haraf D, Kies M, Stenson K, Portugal L, List M, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clinical Cancer Research 2003;9(5):1689-1697
12. Antonadou D, Varveris P, Kyprianou C, Coliarakis N, Athanasiou H, Papadopoulos V, et al. A multicenter, open study evaluating the impact of darbepoetin alfa on anaemia and quality of life, in cancer patients undergoing radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2005;63(2):S82-3.
13. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, et al. Impact of hemoglobin (Hgb) level and use of recombinant human erythropoietin (r-HuEPO) on response to neoadjuvant chemoradiation therapy, tumor control, and survival in patients with oral or oropharyngeal squamous cell carcinoma (SCCA). International Journal of Radiation Oncology, Biology, Physics 1999;45(3):S149-50.
14. Glaser M, Millesi W, Kornek G, Lang S, Schüll B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative hemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. International Journal of Radiation Oncology, Biology, Physics 2001;50(3):705-715 (Pubitemid 32519598)
15. Lambin P, Bernier J, Denham J, Sureda A, Bourhis JH, Kaldau F, et al. A phase III double-blind, randomized, placebo-controlled study of erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma [EORTC protocol 22996-24002]. http://clinicaltrials.gov/ ct2/show/NCT00017277 2001.
16. Lavey R, DempseyW. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. International Journal of Radiation Oncology, Biology, Physics 1993;27(5):1147-1152 (Pubitemid 23361597)
17. Martinez J, Espineira M, Cabezon M, Villar A, Perez M, Borque C, et al. Hyperfractionated chemoradiotherapy with carbogen breathing, and with or without erythropoietin for head and neck cancer. Radiotherapy and Oncology 2001;58(Suppl 1):S93.
18. Martinez J, Villar A, Cabezon M, Serdio J, Fuentes C, Neira M, et al. Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2001;50(1):47-53.
19. Murphy B, Shaktour B, Raben D, Reid W, Weng E, Burkey B, et al. A phase II multi-institutional trial of chemoradiation (CR) using weekly docetaxel (Doc) and erythropoetin (Epo) for high-risk postoperative head and neck cancer (HRHNC) patients. Journal of Clinical Oncology 2005;23(Suppl 1):5591.
20. Samper P, Vallejo C, Lopez-Carrizosa C, Rodriguez A, Saez J, Delgado J. Comparison of darbepoetin alfa and epoetin alfa for radiotherapy (RT) or chemoradiotherapy (CT/RT)-induced anemia. International Journal of Radiation Oncology, Biology, Physics 2005;63(Suppl 1):S479.
21. Scott S, Boeve T, McCulloch T, Fitzpatrick K, Karnell L. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 2002;112(7):1221-1229 (Pubitemid 34747219)
22. Tsukuda M, Mochimatsu I, Nagahara T, Kokatsu T, Sawaki S, Kubota A, et al. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer. Cancer Immunology, Immunotherapy 1993;6(1):52-56
23. Villar A, Martinez J, Fuentes C, Cabezon M, Perez M, Espiñeira M, et al. The use of erythropoietin instead of transfusions to correct anemia in hyperfractionated chemoradiation of advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 2001;51(3):367.
24. Willey C, Murphy B, Netterville J, Burkey B, Shyr Y, Shakhtour B, et al. A phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics 2007;67(5):1323-1331 (Pubitemid 46467165)
25. Aziz K, Hashem T, Mobarek N, Bary N, Ghoneimy I, Haddad S. Does recombinant human erythropoietin improve the outcome of radiation therapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics 2001;51(3, Suppl 1):367.
26. Elsaid A, FaroukM. Significance of anemia and role of erythropoietin in radiation induced mucositis in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics 2001;51(3, Suppl 1):368.
27. Bohlius JF, Langensiepen S, Engert A, Schwarzer G, Bennett CL. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Practice & Research. Clinical Haematology 2005;18(3):449-454 (Pubitemid 40425357)
28. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. [Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.pub4]
29. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology 1999;53(2):113-117
30. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research 1998;58(7):1408-1416
31. Bokemeyer C, Aapro M, Courdi A, Foubert J, Link H, Österborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer 2007;43:258-270 (Pubitemid 44063352)
32. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiotherapy and Oncology 1998;48(2):149-156 (Pubitemid 28423786)
33. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
34. Harari PM, Mehta MP, Ritter MA, Petereit DG. Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. Seminars in Radiation Oncology 2003;13(1):3-12.
35. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-1260 (Pubitemid 37324251)
36. Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. Journal of Clinical Oncology 2006;24:4708-4713 (Pubitemid 46630934)
37. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 1996;56(19):4509-4515 (Pubitemid 26330463)
38. Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al. Definitive radiotherapy ± erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. International Journal of Radiation Oncology, Biology, Physics 2004;60(1 (Suppl 1)):s132.
39. NordsmarkM, OvergaardM, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 1996;41(1):31-39 (Pubitemid 26396294)
40. TheNordic Cochrane Centre, TheCochrane Collaboration. Review Manager (RevMan). 5.0 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.